ModerateMacrolide antibiotic×Atypical antipsychotic – dopamine and serotonin receptor antagonist
Updated · Methodology
Mechanism
Erythromycin prolongs the QT interval on the electrocardiogram, and torsade de pointes and deaths have been reported with it (erythromycin labels). With risperidone, QT prolongation has been reported very rarely after marketing and also in overdose. In controlled adult trials, mean changes in QT and corrected QT (QTc) did not differ significantly from placebo (risperidone labels). Taken together, the effects of the two drugs on the heart may add up. The labels of both call for caution with other drugs that prolong the QT interval. The liver breaks down risperidone mainly through CYP2D6 and to a lesser extent through CYP3A4, which erythromycin inhibits. Still, erythromycin 500 mg four times a day barely changed blood levels of risperidone and its active metabolite (risperidone labels).
Symptoms
QT prolongation itself causes no symptoms and shows only on the electrocardiogram (ECG). The danger is ventricular arrhythmia: torsade de pointes, ventricular tachycardia, ventricular fibrillation and even cardiac arrest and sudden death (risperidone and erythromycin labels). An arrhythmia episode presents as palpitations, dizziness or fainting. The risk is higher with low potassium or magnesium, clinically relevant bradycardia, coronary artery disease, severe heart failure, conduction disorders, a family history of QT prolongation and in older people (erythromycin and risperidone labels).
Management
Use the combination with caution: the Spanish risperidone and erythromycin labels ask for caution with any drug that prolongs the QT interval (risperidone and erythromycin labels, Spanish Agency of Medicines and Medical Devices, AEMPS). Do not adjust the risperidone dose because of erythromycin: according to the Spanish label, erythromycin does not change risperidone pharmacokinetics (AEMPS). The US label also states that no dose adjustment is needed (risperidone label, US Food and Drug Administration, FDA). Do not give erythromycin to patients with a history of QT prolongation or ventricular arrhythmia, including torsade de pointes, or with low potassium or magnesium (erythromycin labels, AEMPS). Use erythromycin with caution in coronary artery disease, severe heart failure, conduction disorders, clinically relevant bradycardia and in older people (erythromycin label, AEMPS). Check blood electrolytes when there is a risk of imbalance, for example with vomiting and diarrhoea or in patients taking diuretics (erythromycin label, AEMPS). Use risperidone with caution in cardiovascular disease, a family history of QT prolongation, bradycardia and low potassium or magnesium (risperidone label, AEMPS). The Spanish label of one intravenous erythromycin product (Panpharma, registration number 79380) lists use with certain QT-prolonging neuroleptics among its contraindications without naming them. The labels of the original intravenous product and of oral forms ask only for caution with such drugs (erythromycin labels, AEMPS). The Panpharma label does not name risperidone, and the risperidone labels give no grounds to count it among these neuroleptics: the warnings mention QT prolongation only as very rare postmarketing reports, and in controlled trials mean QT changes did not differ from placebo (risperidone labels). Before prescribing erythromycin, weigh the benefit of treatment against the risk of cardiac complications (erythromycin labels, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Eritromicina (nº registro 79380), sección 4.3 (2025)– AEMPS, CIMA, nº registro 79380, sección 4.3
- AEMPS: Ficha técnica: Eritromicina (nº registro 57474), sección 4.4 (2024)– AEMPS, CIMA, nº registro 57474 (Pantomicina 500 mg comprimidos), revisión 05/2024, secciones 4.3, 4.4 y 4.5
- FDA: E.E.S. (erythromycin ethylsuccinate) prescribing information (2025)– FDA, DailyMed, Carnegie Pharmaceuticals LLC, setid 91479d92-3bf3-4eb3-81bd-8ce4956d4347, revised 02/2025, Contraindications, Warnings – QT Prolongation, Precautions – Drug Interactions
- AEMPS: Ficha técnica: Risperidona (nº registro 70047), sección 4.5 (2021)– AEMPS, CIMA, nº registro 70047 (Risperidona Cinfa 1 mg/ml solución oral EFG), revisión del texto 11/2021, secciones 4.4, 4.5, 4.8 y 4.9
- AEMPS: Ficha técnica: Eritromicina (nº registro 55771), sección 4.3 (2025)– AEMPS, CIMA, nº registro 55771 (Pantomicina 1 g polvo para solución para perfusión), revisión 09/2025, secciones 4.3, 4.4 y 4.5
- FDA: Risperdal (risperidone) prescribing information (2026)– FDA, DailyMed, Janssen Pharmaceuticals, setid 7e117c7e-02fc-4343-92a1-230061dfc5e0, version 45, effective 05/2026, sections 4, 6.1, 6.2, 7.1 (Table 18) and 10.1